Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant anti-CD25 humanized monoclonal antibody induction regimen for prevention of acute rejection after kidney transplantation
ChiCTR2400083281Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daclizumab in kidney allograft rejection, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Incidence of acute rejection within 6 months after transplantation and Changes in serum interleukin-2 receptor level. Started Apr 2024; status: recruiting.
02
Drugs
daclizumab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on ChiCTR2400083281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083281.